---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-025003"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:00:30.646980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acurx launches ibezapolstat pilot trial in recurrent CDI; Phase 2 showed 96% cure, no recurrence

## Summary
- CEO, Executive Chairman, CFO take 10% base salary cut; director cash retainers also reduced 10%, effective April 1, 2026.
- Acurx opens open-label pilot trial for ibezapolstat in multiply-recurrent CDI (up to 20 patients); first enrollment expected Q4 2026.
- Phase 2 data: ibezapolstat achieved 96% clinical cure (25/26) and 100% sustained cure with no recurrence at 1 month (25/25).
- Beneficial gut microbiome preservation and bile acid data suggest potential for single-agent treatment and prevention of rCDI.
- Company plans to seek FDA approval under LPAD pathway for rCDI treatment and prevention after Phase 3.

## SEC filing metadata
- accession: 0001104659-26-025003
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465926025003/0001104659-26-025003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465926025003/tm268319d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-025003
- JSON: https://secwatch.observer/filing/0001104659-26-025003.json
- Plain text: https://secwatch.observer/filing/0001104659-26-025003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.